{"url_path":"/sec/ppcb/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 Unregistered Sales of Equity Securities and Use of Proceeds.**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1517681/0001493152-26-023210-index.html","accession_number":"0001493152-26-023210","cik":"0001517681","ticker":"PPCB","issuer_name":"Propanc Biopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1517681/0001493152-26-023210-index.html","primary_entity_key":"0001517681","primary_entity_name":"Propanc Biopharma, Inc."},"word_count":399,"has_tables":true,"body_markdown":"**\n\n**Item\n2. Unregistered Sales of Equity Securities and Use of Proceeds.**\n\n \n\nIn\nJanuary 2026, the Company issued an aggregate of 14,805 shares of common stock for services rendered and to be rendered from December\n26, 2025 to March 26, 2026 in connection with the Advisory agreement dated on September 25, 2025. These shares were valued at approximately\n$0.51 or $7,500, being the closing price of the stock on the date of grant.\n\n \n\nOn\nJanuary 7, 2026, the Company entered into an Exchange Agreement with Crown Bridge and issued 394,788 shares of common stock in exchange\nfor the total outstanding loan balance of $65,280 and accrued interest of $60,484. Those shares were valued at approximately $0.51 per\nshare or $200,000, being the closing price of the stock on the date of grant.\n\n \n\nOn\nMarch 16, 2026, the Company granted an aggregate of 25,500,000 shares of common stock to certain officers, employees, directors and consultants\nfor services rendered. Those shares were valued at approximately $0.14 per share or $3,570,000, being the closing price of the stock\non the date of grant. During the nine months ended March 31, 2025, the Company recorded stock-based compensation of $3,570,000 related\nto such grant. These 25,500,000 shares were issued on April 28, 2026 and were considered shares issuable as of March 31, 2026.\n\n \n\nOn\nMarch 16, 2026, the Company granted an additional 7,500,000 shares of fully vested, non-forfeitable common stock to various consultants\nfor consulting, investor relations and business advisory services related to existing 3-year consulting agreements dated between January\n2025 and March 2025. Those shares were valued at approximately $0.14 per share or $1,050,000, being the closing price of the stock on\nthe date of grant. These 7,500,000 shares were issued on April 28, 2026 and were considered shares issuable as of March 31, 2026.\n\n \n\n*Except\nas otherwise noted, the securities in the transactions described above were sold in reliance on the exemption from registration provided\nin Section 4(a)(2) of the Securities Act and/or Rule 506(b) promulgated thereunder, as there was no general solicitation to the investors\nand the transactions did not involve any public offering. All certificates evidencing the shares sold bore a restrictive legend. No underwriter\nparticipated in the offer and sale of these securities, and no commission or other remuneration was paid or given directly or indirectly\nin connection therewith. The proceeds from these sales were used for general corporate purposes.*"}